EP Patent

EP0605203A2 — Antiallergic composition for ophthalmic or nasal use

Assigned to UCB Farchim SA · Expires 1994-07-06 · 32y expired

What this patent protects

There is disclosed an antiallergic composition for ophthalmic or nasal use, comprising cetirizine or a salt thereof as an active ingredient. The antiallergic composition may further contain a cyclodextrin compound, as well as a surfactant and/or a water soluble polymer.

USPTO Abstract

There is disclosed an antiallergic composition for ophthalmic or nasal use, comprising cetirizine or a salt thereof as an active ingredient. The antiallergic composition may further contain a cyclodextrin compound, as well as a surfactant and/or a water soluble polymer.

Drugs covered by this patent

levocetirizine-dihydrochloride (LEVOCETIRIZINE DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP0605203A2
Jurisdiction: EP
Classification: —
Expires: 1994-07-06
Drug substance claim: No
Drug product claim: No
Assignee: UCB Farchim SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.